Advances in Gene Editing Technologies in Healthcare

Why Is It Increasingly Difficult To Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Gene Editing Technology Industry

Growth Opportunities Fuel The Growth Pipeline Engine™

Research Context

Research Coverage and Key Questions the Study Will Answer

Research Methodology

Development of Gene Editing Tools

Technology Assessment of Gene Editing Tools

Research Hubs for Gene Editing Technology

Uses of Gene Editing Technology in the Clinic—Therapeutics and Diagnostics

Growth Drivers

Growth Driver Analysis

Growth Restraints

Growth Restraint Analysis

Emerging Trends in the Adoption of Genome Editing in the Clinic

Technology Developments around CRISPR-Cas

Technology Developments around CRISPR-Cas to Improve Delivery

Technology Developments around CRISPR-Cas to Improve Precision

Next-generation Gene Editing Technology

Next-generation Gene Editing Technology (continued)

Next-generation Gene Editing Technology (continued)

Next-generation Gene Editing Technology (continued)

Emerging Participants Working on Next-generation CRISPR Technology

Emerging Technology Developers Leveraging CRISPR

CRISPR/Cas: Applications across Indications

CRISPR/Cas: Applications across Indications (continued)

Major Participants Developing CRISPR-based Therapeutics

Major Participants Developing CRISPR-based Therapeutics (continued)

Development of CRISPR-based Gene Editing as Targeted Antibacterials

Development of CRISPR-based Gene Editing as Targeted Antivirals

Non-CRISPR-based Therapeutics

Major Participants Developing Non-CRISPR-based Therapeutics

Development of Gene Editing Tools in Diagnostics

CRISPR-Cas System-based Diagnostic Tools

CRISPR-Cas System-based Diagnostic Tools (continued)

Gene Editing Strategies: Developments in In Vivo and Ex Vivo Gene Editing Tools

Challenges and Limitations of Gene Editing Delivery Systems

Developments in Gene Editing Delivery

Current Approaches for Gene Editing Delivery

Current Approaches for Gene Editing Delivery (continued)

Developments in Viral Vectors for Gene Editing Delivery

Developments in Viral Vectors for Gene Editing Delivery (continued)

Developments in Nonviral Vectors for Gene Editing Delivery Carriers – Lipid-based Formulations

Developments in Nonviral Vectors for Gene Editing Delivery Carriers – Lipid-based Formulations (continued)

Cell/Cell Component-derived Carriers

Cell/Cell Component-derived Carriers (continued)

Polymer-based Formulations

Peptide-based Formulations

Development of Other Nanoscale Gene Editing Delivery Carriers

Development of Other Nanoscale Gene Editing Delivery Carriers (continued)

Nanoparticles

Nanoparticles (continued)

Development of Physical Methods of Delivery of Gene Editing Therapeutics

Development of Physical Methods of Delivery of Gene Editing Therapeutics (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)

Technology Licensing

Technology Licensing(continued)

Acquisitions

Highlights of Gene Edited Therapeutics and Diagnostic Development Collaborations

Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022)

Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022) (continued)

Funding Analysis of Gene Editing Companies

Funding Analysis of Gene Editing Companies (continued)

Key Takeaways

Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools

Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools (continued)

Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities

Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities (continued)

Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe

Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe (continued)

Future Outlook of Gene Editing Applications beyond Healthcare

Future Outlook of Gene Editing Applications beyond Healthcare (continued)

Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches

Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches (continued)

Existing Gene Editing Delivery Vectors

Existing Gene Editing Delivery Vectors (continued)

Technology Readiness Levels (TRL): Explanation

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer